POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA

Askanase, A., Stach, C., Brittain, C., Stojan, G., & Furie, R. (2023). POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.1991
Authors:
Anca Askanase
C. Stach
Clare Brittain
George Stojan
Richard Furie
Affiliated Authors:
Anca Askanase
Columbia Affiliation:
Subjects:
Systemic Lupus Erythematosus and Antiphospholipid Syndrome (OpenAlex Topic)
Therapeutic Antibodies: Development, Engineering, and Applications (OpenAlex Topic)
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1136/annrheumdis-2023-eular.1991
DOI:
10.1136/annrheumdis-2023-eular.1991
Journal:
Annals of the Rheumatic Diseases
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: